comparemela.com

Latest Breaking News On - Hedge funds weigh in on jazz pharmaceuticals - Page 3 : comparemela.com

Jazz Pharmaceuticals (NASDAQ:JAZZ) Receives New Coverage from Analysts at Raymond James

Equities research analysts at Raymond James assumed coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) in a note issued to investors on Thursday, FlyOnTheWall reports. The brokerage set a “market perform” rating on the specialty pharmaceutical company’s stock. Other analysts have also recently issued reports about the company. Needham & Company LLC […]

Patricia Carr Sells 158 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) CAO Patricia Carr sold 158 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $138.16, for a total value of $21,829.28. Following the completion of the sale, the chief accounting officer now owns […]

Bank of America Raises Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $217 00

Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its price objective raised by Bank of America from $204.00 to $217.00 in a research note published on Thursday morning, Marketbeat Ratings reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. A number of other analysts also recently issued reports on JAZZ. StockNews.com […]

Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues FY 2023 Earnings Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) updated its FY 2023 earnings guidance on Thursday. The company provided EPS guidance of $18.15-$19.00 for the period, compared to the consensus EPS estimate of $17.48. The company issued revenue guidance of $3.73 billion-$3.88 billion, compared to the consensus revenue estimate of $3.78 billion. Analyst Ratings Changes A […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.